Eli Lilly vs Novo Nordisk vs Pfizer: One Megatrend, Three Wildly Different Outcomes

One drug category reshaped three of the world's biggest pharma companies in completely opposite directions. Eli Lilly (LLY) just hit an all-time high of $1,182.73 on June 8, 2026, currently trades around $1,098, barely 7% off that peak, and now holds 60% of the US obesity drug market. Novo Nordisk (NVO), the company that built this entire GLP-1 drug category from scratch with Ozempic and Wegovy, is down 70% from its June 2024 high of $148.15, now at $43.19. Pfizer (PFE), which barely made it into the category at all, sits 60% below its December 2021 all-time high of $61.71, trading at $25.21. Same sector. Same macro tailwind. Three stories that couldn't be more different.

Let's break down what actually drove this divergence, why Lilly got it so right while the other two struggled, and what an Indian investor looking for US pharma exposure should genuinely think about before putting money to work here.

How GLP-1 Drugs Changed Eli Lilly, Novo Nordisk and Pfizer Stocks

GLP-1 drugs, medicines that regulate appetite and blood sugar, are now the single most consequential drug category on earth. The market is forecast to exceed $150 billion annually within this decade, as per Bloomberg Intelligence projections cited across multiple earnings calls and investor presentations.

Two of our three companies entered this race at roughly the same time. One came away as the market leader. The other lost nearly three-quarters of its market value trying to keep up. The third never really competed and is now scrambling to buy its way in.

Here's the clearest analogy for how this played out. Think back to India's 4G telecom war. Novo Nordisk was Airtel: the pioneer, the established brand, years of dominance. Eli Lilly was Jio: arrived slightly later but launched with a product that was clinically proven to be superior, and took market share faster than almost anyone expected. Pfizer? It tried to build its own version of a 4G network (an oral GLP-1 drug called danuglipron), ran into serious tolerability problems in clinical trials, and dropped the program in April 2025. It's now trying to buy its way into the race through acquisitions.

Understanding this framing makes the valuation gap far easier to read.

Eli Lilly vs Novo Nordisk vs Pfizer: Revenue, Products and Dividend Snapshot

Source: Eli Lilly Q1 2026 8-K; Novo Nordisk FY2025 6-K; Pfizer Q1 2026 8-K (SEC filings)

All three are global biopharmaceutical companies. But their financial trajectories today are pointing in completely different directions.

Eli Lilly: The Blueprint for Getting a Megatrend Right

The short version is clinical superiority, executed at commercial scale, backed by patent protection lasting into the 2030s.

Lilly's tirzepatide (sold as Mounjaro for diabetes and Zepbound for obesity) works on two receptor pathways, GLP-1 and GIP, while Novo's semaglutide (Ozempic/Wegovy) acts on only one. In a direct head-to-head clinical trial conducted by Lilly in 2024 (SURMOUNT-5), tirzepatide produced measurably greater weight loss than semaglutide. Prescribers read the data and responded. As per CNBC's coverage of Lilly's Q1 2026 earnings, Lilly held 60.1% of the combined US obesity and diabetes GLP-1 market in that quarter.

The numbers behind this shift are hard to ignore. Q1 2026 total revenue came in at $19.8 billion, up 56% year over year, per Lilly's Q1 2026 8-K. Mounjaro alone generated $8.66 billion in worldwide sales in that quarter, up 125% year over year, overtaking Merck's Keytruda as the world's highest-grossing drug. Zepbound added $4.16 billion in US revenue, up 80%, as per CNBC's April 30, 2026 earnings coverage. The company raised its full-year guidance to $82-$85 billion in revenue and $35.50-$37.00 in adjusted EPS.

And then it added another card. Foundayo, Lilly's FDA-approved oral GLP-1 pill, launched in Q2 2026. Unlike Novo's oral Wegovy tablet, which carries specific instructions around food and water timing, Foundayo can be taken any time of day, without food or water restrictions, per CEO David Ricks in the Q1 2026 earnings call. That usability edge matters for a daily pill competing with an injection for patient adherence. In 2027, Lilly plans to launch retatrutide, a triple receptor agonist that acts on three pathways. Ricks has said tirzepatide's patents in major markets are protected into "the back half of the 2030s," as per CNBC's February 2026 reporting.

The one number that does give pause: Mounjaro and Zepbound together made up approximately 65% of Lilly's Q1 2026 total revenue, as per IndexBox's June 2026 analysis. For a $980 billion company, that's a significant dependency. If pricing policy, competition, or patient access suddenly shifts, the concentration is a real vulnerability.

Novo Nordisk: From World-Beater to Freefall, What Actually Happened?

Novo invented this category. Ozempic launched in 2017. Wegovy in 2021. For years the company seemed almost unstoppable, and its stock reflected that. Then three things broke the story.

1. Compounding pharmacies took share first. When Wegovy supply was short, the FDA's shortage rules allowed compounding pharmacies to make essentially generic semaglutide at a fraction of the branded price. Novo's own FY2025 6-K to the SEC acknowledges "persistent use of compounded GLP-1s" and "slower-than-expected market expansion" in the US as primary reasons for the Wegovy sales miss. The FDA's grace period for mass compounders expired in May 2025, but Novo's 6-K notes that mass compounding continued illegally after that, with the company pursuing litigation.

2. Lilly's tirzepatide then proved clinically better. Once prescribers had both the head-to-head data and the actual prescription trends in front of them, they started switching patients. Novo began losing US GLP-1 market share from mid-2024, as per Motley Fool's February 2026 analysis of company data.

3. Then CagriSema failed. This was supposed to be Novo's answer, a next-generation combination drug designed to decisively outperform tirzepatide on weight loss. On February 23, 2026, Novo announced that CagriSema had failed its primary endpoint of demonstrating non-inferiority against Lilly's tirzepatide. The stock fell over 16% in a single day, as per CNBC's February 24, 2026 report. That was the company's biggest single-day drop in years.

Add in a CEO transition (Lars Fruergaard Jørgensen replaced by Maziar Mike Doustdar), guidance for a 5-13% sales decline at constant exchange rates in 2026 as per its FY2025 6-K, and US drug pricing headwinds from the Most Favoured Nations policy, and the 70% drawdown from the ATH starts to make sense.

But here's what the fully bearish case misses. Novo's oral Wegovy pill, launched in January 2026, had already passed 2 million US prescriptions since launch by Q1 2026, as per Capital.com's coverage of Novo's Q1 earnings. International Ozempic hit an all-time sales high in Q1 2026, as per Novo's Q1 2026 6-K. Bernstein upgraded Novo to Outperform in 2026. JPMorgan's analyst Richard Vosser called the selloff on Novo's Alzheimer's-related miss "overdone," as per TipRanks. Novo's new CEO told CNBC bluntly: "People should expect that it goes down before it comes back up."

At approximately 13x forward earnings versus a historical average of 23-26x,as per FinanceCharts data, Novo has priced in a lot of bad news. The question is whether the bad news has finished arriving.

Pfizer: The COVID Hangover, a $50 Billion M&A Gamble, and a 6.8% Dividend

Pfizer's situation is the most straightforward to explain, and the hardest to invest in.

The company earned $100.3 billion in revenue in 2022, almost entirely because of the pandemic, as per Labiotech.eu's April 2026 reporting. Comirnaty (its COVID vaccine) and Paxlovid (its antiviral) were once pulling in tens of billions annually. By 2023, Paxlovid revenue fell 95% year over year, as per Pfizer's Q3 2023 8-K. The stock has never recovered from that cliff.

To replace the lost revenue, Pfizer acquired Seagen for approximately $43 billion in 2023, betting on antibody-drug conjugates (ADCs) as the future of cancer treatment. That bet is producing early results: Padcev, Seagen's bladder cancer drug, grew 39% in recent reporting, and oncology now accounts for approximately 27% of Pfizer's total revenue, as per Dividend Growth Lab's June 2026 analysis. Pfizer then acquired Metsera in late 2025 for around $7-10 billion to gain a clinical-stage obesity pipeline, winning a bidding contest that reportedly also involved Novo Nordisk.

The problem is the balance sheet. Long-term debt stood at approximately $60.6 billion as of Q1 2026, as per Pfizer's 10-Q. There are no share buybacks. The dividend, while covered at around 60% of adjusted earnings as per Pfizer's own guidance, has not been raised in recent periods. The company's 2026 adjusted EPS guidance of $2.80-$3.00 per share is essentially flat to its post-COVID reset.

At $25.21, the forward adjusted P/E sits around 8.7x; very cheap in absolute terms. The 6.8% dividend yield is genuinely attractive for income-focused investors. But cheap multiples on declining earnings with a heavy debt load are a warning to take seriously, not a screaming signal on their own.

Eli Lilly, Novo Nordisk and Pfizer Stock Forecasts: Analyst Ratings and Price Targets

Source: S&P Global Market Intelligence, TipRanks, MarketBeat, Benzinga analyst data as of June 2026.

LLY vs NVO vs PFE: Valuation, EPS Growth, Debt and Dividend Comparison

Source: Eli Lilly, Novo Nordisk, and Pfizer SEC filings (Q1 2026 8-K, 10-Q, and 6-K); Yahoo Finance; Macrotrends.

There's a valuation framework worth applying here called the PEG ratio: Price/Earnings relative to Earnings Growth. For Lilly, at 30x forward earnings with EPS growing at around 50% year over year, the PEG sits around 0.6x. Growth investors typically treat below 1x PEG as attractive relative to the growth rate on offer. That's the mathematical argument for why Lilly's 7% pullback from its all-time high looks less expensive than the headline multiple suggests.

For Novo at 13x forward earnings on declining EPS, there's no positive PEG argument. The case for Novo is mean reversion; the stock has historically traded at 23-26x earnings, and if earnings stop falling (or start recovering), the multiple could re-rate upward. That requires a catalyst, not just time.

For Pfizer at 8.7x forward adjusted earnings, the valuation looks cheap in isolation. But declining earnings and $60 billion in debt make this more of an income-and-wait story than a growth story.

Our Take: Three Pharma Playbooks, Three Different Investors

These three stocks don't compete for the same type of investor. Each represents a distinct thesis.

1. The Quality Momentum Playbook (LLY): You're paying roughly 30x forward earnings for a company with 50%+ EPS growth, a new oral pill with a genuine usability advantage over Novo's version, a decade of patent protection, and the world's single best-selling drug in Mounjaro. The 7% pullback from the all-time high is within the normal range for a high-multiple growth stock digesting a run. On a PEG basis, it's arguable that Lilly is actually less expensive than it was at its peak. The concentration risk in two drugs is the biggest real danger here. What would flip this thesis is that oral Wegovy surprises with faster-than-expected traction, Lilly's pricing realization drops more than mid-teens under the MFN policy, or Novo's next-generation amycretin pill (currently in Phase 3) produces data that matches or beats Foundayo.

2. The Contrarian Recovery Playbook (NVO): You're buying after 70% of the bad news has presumably been priced in. CagriSema failed. The CEO is new. Earnings are falling. But at 13x forward earnings versus a historical 23-26x, the market has already stripped out most of the premium. The recovery case depends on oral Wegovy prescription growth accelerating through broader insurance payer access, international Ozempic continuing its record run, and CagriSema still getting an FDA decision in late 2026 (the FDA submission is still active, as per the FY2025 6-K). This is a patience play for investors who believe the franchise isn't broken, just disrupted. What would flip this thesis is that Lilly's Foundayo dominates oral GLP-1 completely before Novo establishes its pill, Novo's amycretin Phase 3 disappoints too, or US MFN pricing erodes international revenue assumptions.

3. The Income and Optionality Playbook (PFE): You collect a 6.8% dividend on a megacap pharma company while waiting for $50 billion worth of acquisitions (Seagen in oncology, Metsera in obesity) to start showing up in earnings. Padcev's 39% growth is a genuine data point that the Seagen bet is working. The 20 pivotal trials starting in 2026 offer optionality, even if none of them are a sure thing. The honest risk is that Metsera's obesity candidates fail Phase 3, patent cliffs between 2026 and 2028 hit harder than modeled, and the dividend gets cut to service debt. The adjusted payout ratio is currently below 65% of adjusted EPS, as per Pfizer's 2026 guidance, which suggests the dividend isn't in immediate danger, but investors should not treat it as guaranteed. For investors willing to hold 2-3 years and collect income while waiting for the rebuild to play out, this is an interesting asymmetric setup. For investors expecting a quick recovery in the stock price, the path is much less clear.

Lilly earned its premium by being better clinically, executing commercially, and locking in a long runway of patent protection. Novo got disrupted in the market it created and is spending 2026 rebuilding from a position of weakness. Pfizer is paying for decisions made during a once-in-a-generation pandemic windfall, and its recovery depends on acquisitions that are just starting to deliver data.

None of these are straightforward "buy the dip" situations. Each demands a specific thesis, a specific time horizon, and a clear understanding of what could go wrong.